The Maze Therapeutics, Inc. (Nasdaq: MAZE) SEC filings page brings together the company’s public regulatory disclosures, offering a detailed view of how this clinical-stage biopharmaceutical company reports its activities to U.S. regulators. Maze focuses on small molecule precision medicines for kidney and metabolic diseases, and its filings provide context on both its scientific programs and its capital markets activity.
Maze’s filings include current reports on Form 8-K, which the company uses to announce material events such as quarterly financial results, leadership changes, and financing transactions. For example, Maze has filed 8-Ks to furnish press releases on second and third quarter financial results, to disclose an oversubscribed private placement of common stock and pre-funded warrants, and to document the appointments of a new chief financial officer and a new chairman of the board.
Investors can also review registration statements, such as the company’s Form S-1, which describes Maze’s business, risk factors, and the resale of shares issued in its 2025 private placement. The S-1 outlines Maze’s focus on human genetics, its Compass platform, and its lead programs MZE829 and MZE782, while also confirming its status as an emerging growth company and smaller reporting company.
Through Stock Titan, these filings are updated in near real time from the SEC’s EDGAR system, and AI-powered summaries help explain the key points of lengthy documents. Users can quickly understand what a particular 8-K, S-1, or other filing means for the company without reading every page. Where applicable, filings related to equity financings, registration rights, and governance changes are highlighted so investors can track dilution, board composition, and executive appointments.
For MAZE, monitoring SEC filings is especially relevant for understanding clinical development disclosures, financing capacity, and risk factors associated with its kidney and metabolic disease programs. This page serves as a central resource for reviewing those official documents alongside concise AI-generated explanations.
Maze Therapeutics, Inc. CSBO Atul Dandekar exercised options covering 6,643 and 857 shares on October 29, 2026, each at an exercise price of $10.42 per share, acquiring the corresponding common shares. The options expire April 11, 2031, and April 23, 2034, respectively. He sold 7,500 common shares that day at a weighted average price of $32.0709 per share; the reported sale prices ranged from $31.61 to $32.56 per share. These transactions were effected under a Rule 10b5-1 trading plan adopted September 29, 2025. The 6,643-share option was fully vested on March 17, 2025; the 857-share option vests in monthly 1/48th tranches, subject to continued service.
Maze Therapeutics, Inc. officer Atul Dandekar reported an intended sale of 15,000 common shares, with an aggregate market value of $475,950.00 and an approximate sale date of October 29, 2026. The notice says the shares to be sold were and will be received upon exercise of stock options over the next three months, and that acquisition and payment dates were and will be the dates of exercise or sale. It also lists earlier 10b5-1 sales of 7,500 common shares on September 29, 2026, for $202,920.75 and 7,500 on August 28, 2026, for $206,823.75.
Maze Therapeutics, Inc. entered into an exchange agreement on October 15, 2026, under which it exchanged an aggregate of 2,776,007 common shares held by Frazier Life Sciences Public Fund, L.P., Frazier Life Sciences X, L.P., Frazier Life Sciences XI, L.P. and Frazier Life Sciences XII, L.P. for pre-funded warrants to purchase an aggregate of 2,776,007 common shares. The warrants have an exercise price of $0.001 per share and may be exercised at any time after issuance.
The warrants cannot be exercised if doing so would cause the exchanging stockholder to beneficially own more than 9.99% of outstanding common stock, subject to certain exceptions. Maze reported 53,931,889 common shares outstanding as of October 16, 2026, after giving effect to the exchange. The warrant holders cannot vote the underlying shares except to the extent required by Delaware law. The warrants will be issued without Securities Act registration in reliance on the Section 3(a)(9) exemption.
Maze Therapeutics, Inc. CEO and director Jason V. Coloma reported sales of 2,593 shares held by The Coloma 2021 Irrevocable Trust at a weighted average price of $27.0241 per share and 31,908 shares held by Coloma Family Trust at a weighted average price of $27.0210 per share on October 1, 2026. Both sales were made under a Rule 10b5-1 trading plan adopted by Coloma on February 6, 2026. After the transactions, the trusts held 15,558 and 191,447 shares, respectively. A separate direct holding entry lists 27,362 shares.
Maze Therapeutics, Inc. (MAZE) President, R&D & CMO Harold Bernstein exercised options for 16,141 shares of common stock at an exercise price of $10.42 per share on October 1, 2026, and sold those 16,141 shares at a weighted average of $26.9341 per share under a Rule 10b5-1 plan adopted September 29, 2025. The sale prices ranged from $26.56 to $27.47 per share. After the exercise, options covering 144,521 shares remained.
Harold Bernstein, an officer of Maze Therapeutics, reported an intended sale of 16,141 common shares, with an aggregate market value of $438,712.38, proposed for October 1, 2026; Morgan Stanley Smith Barney LLC is listed in connection with the sale. The shares are listed as acquired from the issuer through exercise of stock options for cash on October 1, 2026. The notice also lists four common-stock sales during the prior three months, three identified as 10b5-1 sales.
Maze Therapeutics, Inc. CSBO Atul Dandekar exercised options covering 7,500 common shares on September 29, 2026, at an exercise price of $10.42 per share, and sold 7,500 shares that day at a weighted average price of $27.0561 per share. The sales occurred in multiple transactions priced from $26.47 to $27.45 per share. The transactions were made under a Rule 10b5-1 trading plan adopted September 29, 2025. The option award was fully vested on March 17, 2025, and 6,643 option shares remained after the exercise.
Maze Therapeutics, Inc. officer Jason Coloma reported a proposed sale of 34,501 common shares, with an aggregate market value of $933,252.05 and an approximate sale date of October 1, 2026. The proposed shares are allocated as 2,593 shares under The Coloma 2021 Irrevocable Trust and 31,908 shares under Coloma Family Trust. UBS Financial Services Inc. is listed in the transaction information, with Nasdaq as the market. The notice also lists sales by both trusts on July 1, August 3 and September 1, 2026.
Maze Therapeutics, Inc. (MAZE) reported that Harold Bernstein, President, R&D & Chief Medical Officer, sold 9,705 shares of common stock on September 4, 2026 in a market transaction at a weighted average price of $26.2238 per share. The sale was made under a Rule 10b5-1 trading plan adopted on September 29, 2025, and Bernstein now holds no shares directly after this transaction.
Maze Therapeutics, Inc. (MAZE) has a notice from officer Harold Bernstein under Rule 144 indicating an intention to sell up to 9,705 shares of common stock through Morgan Stanley Smith Barney LLC on or after September 4, 2026, on NASDAQ.
The shares to be sold were acquired as Restricted Stock Units from the issuer on September 1, 2026. Bernstein also reports several common stock sales during the prior three months, including transactions made pursuant to a Rule 10b5-1 trading plan.